Based on recent deals, an effective cancer drug ag
Post# of 72440
I agree that if the K-OC trial is successful, CTIX should have no problem finding partners for other indications.
Quote:
Likely it will get to market for ovarian cancer first, but when CTIX secures a partnership and funding from the other drugs, they may be able to open up several other pathways for K in parallel with the ovarian cancer indication.